Epitope-based vaccination against pneumonic tularemia

Vaccine

Volumn 27, Issue 39, 2009, Pages 5299-5306

  Gregory, Stephen H ^a   Mott, Stephanie ^a   Phung, Jennifer ^a   Lee, Jinhee ^b   Moise, Leonard ^c,d   McMurry, Julie A ^c   Martin, William ^c   De Groot, Anne S ^c,d  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c EpiVax Inc   (United States)

^d UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

DNA vaccine; Francisella tularensis; Lungs

Indexed keywords

DNA VACCINE; EPITOPE; HLA ANTIGEN CLASS 2; TULAREMIA VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; BACTERIAL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; FRANCISELLA TULARENSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE; TULAREMIA; VACCINATION;

ANIMALS; BACTERIAL VACCINES; CYTOKINES; EPITOPES, T-LYMPHOCYTE; FRANCISELLA TULARENSIS; LIVER; LUNG; MICE; MICE, TRANSGENIC; SPLEEN; TULAREMIA; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 68349109567     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.101     Document Type: Article

References (44)

1. Tarnvik A. Nature of protective immunity to Francisella tularensis. Rev Infect Dis 11 3 (1989) 440-451
2. Evans M.E., Gregory D.W., Schaffner W., and McGee Z.A. Tularemia: a 30-year experience with 88 cases. Medicine (Baltimore) 64 4 (1985) 251-269
3. Johansson A., Ibrahim A., Goransson I., Eriksson U., Gurycova D., Clarridge III J.E., et al. Evaluation of PCR-based methods for discrimination of Francisella species and subspecies and development of a specific PCR that distinguishes the two major subspecies of Francisella tularensis. J Clin Microbiol 38 11 (2000) 4180-4185
4. Gill V., and Cunha B.A. Tularemia pneumonia. Semin Respir Infect 12 1 (1997) 61-67
5. American Public Health Association. Chin J, editors. Control of communicable diseases manual. Washington, D.C.: American Public Health Association; 2000; Tularemia. p. 532-5.
6. Dennis D.T., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., et al. Tularemia as a biological weapon: medical and public health management. JAMA 285 21 (2001) 2763-2773
7. Conlan J.W., Sjostedt A., and North R.J. CD4+ and CD8+ T-cell-dependent and -independent host defense mechanisms can operate to control and resolve primary and secondary Francisella tularensis LVS infection in mice. Infect Immun 62 (1994) 5603-5607
8. Fulop M., Mastroeni P., Green M., and Titball R.W. Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine 19 31 (2001) 4465-4472
9. Kirimanjeswara G.S., Golden J.M., Bakshi C.S., and Metzger D.W. Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis. J Immunol 179 1 (2007) 532-539
10. Sjostedt A., North R.J., and Conlan J.W. The requirement of tumour necrosis factor-α and interferon-γ for the expression of protective immunity to secondary murine tularaemia depends on the size of the challenge inoculum. Microbiology 142 Pt 6 (1996) 1369-1374
11. Fortier A.H., Leiby D.A., Narayanan R.B., Asafoadjei E., Crawford R.M., Nacy C.A., et al. Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth. Infect Immun 63 4 (1995) 1478-1483
12. Clemens D.L., Lee B.Y., and Horwitz M.A. Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages. Infect Immun 72 6 (2004) 3204-3217
13. Saslaw S., Eigelsbach H.T., Prior J.A., Wilson H.E., and Carhart S. Tularemia vaccine study, II: respiratory challenge. Arch Int Med 107 (1961) 134-146
14. Cherwonogrodzky J.W., Knodel M.H., and Spence M.R. Increased encapsulation and virulence of Francisella tularensis live vaccine strain (LVS) by subculturing on synthetic medium. Vaccine 12 9 (1994) 773-775
15. Oyston P.C., Sjostedt A., and Titball R.W. Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat Rev Microbiol 2 12 (2004) 967-978
16. Baron S.D., Singh R., and Metzger D.W. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion. Infect Immun 75 5 (2007) 2152-2162
17. Rawool D.B., Bitsaktsis C., Li Y., Gosselin D.R., Lin Y., Kurkure N.V., et al. Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J Immunol 180 8 (2008) 5548-5557
18. Burke D.S. Immunization against tularemia: analysis of the effectiveness of live Francisella tularensis vaccine in prevention of laboratory-acquired tularemia. J Infect Dis 135 1 (1977) 55-60
19. Wayne C.J., and Oyston P.C. Vaccines against Francisella tularensis. Ann N Y Acad Sci 1105 (2007) 325-350
20. Bakshi C.S., Malik M., Mahawar M., Kirimanjeswara G.S., Hazlett K.R., Palmer L.E., et al. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine 26 41 (2008) 5276-5288
21. Conlan J.W., Shen H., Webb A., and Perry M.B. Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine 20 29-30 (2002) 3465-3471
22. McMurry J.A., Gregory S.H., Moise L., Rivera D., Buus S., and De Groot A.S. Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. Vaccine 25 16 (2007) 3179-3191
23. Woods A., Chen H.Y., Trumbauer M.E., Sirotina A., Cummings R., and Zaller D.M. Human major histocompatibility complex class II-restricted T cell responses in transgenic mice. J Exp Med 180 1 (1994) 173-181
24. Kim J., Merry A.C., Nemzek J.A., Bolgos G.L., Siddiqui J., and Remick D.G. Eotaxin represents the principal eosinophil chemoattractant in a novel murine asthma model induced by house dust containing cockroach allergens. J Immunol 167 5 (2001) 2808-2815
25. Larsson P., Oyston P.C., Chain P., Chu M.C., Duffield M., Fuxelius H.H., et al. The complete genome sequence of Francisella tularensis, the causative agent of tularemia. Nat Genet (2005)
26. Takeshita S., Takeshita F., Haddad D.E., Ishii K.J., and Klinman D.M. CpG oligodeoxynucleotides induce murine macrophages to up-regulate chemokine mRNA expression. Cell Immunol 206 2 (2000) 101-106
27. Gursel I., Gursel M., Ishii K.J., and Klinman D.M. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 167 6 (2001) 3324-3328
28. Gehring S., Dickson E.M., San Martin M.E., van Rooijen N., Papa E.F., Harty M.W., et al. Kupffer cells abrogate cholestatic liver injury in mice. Gastroenterology 130 3 (2006) 810-822
29. Saslaw S., Eigelsbach H.T., Wilson H.E., Prior J.A., and Carhart S. Tularemia vaccine study, I: intracutaneous challenge. Arch Int Med 107 (1961) 121-133
30. Pechous R.D., McCarthy T.R., Mohapatra N.P., Soni S., Penoske R.M., Salzman N.H., et al. A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge. PLoS ONE 3 6 (2008) e2487
31. Fulop M., Manchee R., and Titball R. Role of two outer membrane antigens in the induction of protective immunity against Francisella tularensis strains of different virulence. FEMS Immunol Med Microbiol 13 3 (1996) 245-247
32. Fulop M., Manchee R., and Titball R. Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia. Vaccine 13 13 (1995) 1220-1225
33. Conlan J.W., Shen H., KuoLee R., Zhao X., and Chen W. Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an αβ T cell- and interferon gamma-dependent mechanism. Vaccine 23 19 (2005) 2477-2485
34. Elkins K.L., Cowley S.C., and Bosio C.M. Innate and adaptive immunity to Francisella. Ann N Y Acad Sci 1105 (2007) 284-324
35. + T cells for soluble and membrane TNF in control of Francisella tularensis live vaccine strain intramacrophage growth. J Immunol 179 11 (2007) 7709-7719
36. Stenmark S., Sunnemark D., Bucht A., and Sjostedt A. Rapid local expression of interleukin-12, tumor necrosis factor alpha, and gamma interferon after cutaneous Francisella tularensis infection in tularemia-immune mice. Infect Immun 67 4 (1999) 1789-1797
37. Wu T.H., Hutt J.A., Garrison K.A., Berliba L.S., Zhou Y., and Lyons C.R. Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A. Infect Immun 73 5 (2005) 2644-2654
38. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3 2 (2003) 133-146
39. Duckett N.S., Olmos S., Durrant D.M., and Metzger D.W. Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain. Infect Immun 73 4 (2005) 2306-2311
40. Cowley S.C., Goldberg M.F., Ho J.A., and Elkins K.L. The membrane form of tumor necrosis factor is sufficient to mediate partial innate immunity to Francisella tularensis live vaccine strain. J Infect Dis 198 2 (2008) 284-292
41. Metzger D.W., Bakshi C.S., and Kirimanjeswara G. Mucosal immunopathogenesis of Francisella tularensis. Ann N Y Acad Sci 1105 (2007) 266-283
42. Malik M., Bakshi C.S., Sahay B., Shah A., Lotz S.A., and Sellati T.J. Toll-like receptor 2 is required for control of pulmonary infection with Francisella tularensis. Infect Immun 74 6 (2006) 3657-3662
43. Greenbaum D., Colangelo C., Williams K., and Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 4 9 (2003) 117
44. Chiavolini D., Alroy J., King C.A., Jorth P., Weir S., Madico G., et al. Identification of immunologic and pathologic parameters of death versus survival in respiratory tularemia. Infect Immun 76 2 (2008) 486-496